Prognosis of patient progression and outcomes on active surveillance

The prostate cancer research team led by Dr. Peter Pinto at the National Cancer Institute has just published some interesting new information on risk for disease progression in men on active surveillance. … READ MORE …

Chris Haiman is looking for 10,000 black men (with prostate cancer)!

The RESPOND study, which was initiated in July last year, appears to be the largest-ever study of risk factors for prostate cancer among the African American community, and probably among Black men worldwide. … READ MORE …

Can MRI data improve decision-making about the need for a biopsy?

Last week we noted that adding MRI data to the Partin tables and to the Kattan/MSKCC nomograms did not seem to improve the accuracy of prognosis of outcomes after radical prostatectomy. … READ MORE …

Risk for suicide among prostate cancer patients

An article just published in the journal Cancer states that — at least here in the USA — there was no significant increase in risk for suicide within the first year after diagnosis among men diagnosed with prostate cancer between 2000 and 2014 … READ MORE …

Maybe coming soon to a medical center near you?

Our regular readers will remember that we have commented on and off on the development of different types of system that (maybe) can be used to test for risk of cancer based on smell … an ability that has been clearly demonstrated among certain trained dogs and one of two electronic systems. … READ MORE …

A paradigm for the future?

Not so long ago, one of the new immunotherapeutic agents (a PD-1 inhibitor called pembrolizumab or Keytruda) was approved by the US Food and Drug Administration (FDA) for the treatment of so-called microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors — regardless of the biological site of origin of those tumors. … READ MORE …

Can MRI data improve older, pre-treatment, prognostic methods?

An obvious but previously unanswered question has been whether adding data from the results of MRI scans to the data used in the Partin tables and in the pre-surgical Kattan nomogram (also known as the Memorial-Sloan Kettering Cancer Center or MSKCC nomogram) can improve the accuracy of these two commonly used prognostic methods. … READ MORE …

Is Gleason 6 prostate cancer really “more lethal” in black men?

A commentary in Renal and Urology News this morning is entitled “Gleason 6 prostate cancer is more lethal in black men”. … READ MORE …

Vigorous exercise and prostate cancer risk

A new study just published in European Urology appears to have confirmed a connection between regular, vigorous exercise (in men of 45 to 75 years of age) and a reduced risk for aggressive (i.e., advanced and lethal) forms of prostate cancer. … READ MORE …

Understanding “cell-free DNA analysis” in cancer diagnosis and management

We have probably all heard terms like “liquid biopsy” and “genetic screening” and “cell-free” DNA analysis over the past few years. These are all terms related to the use of genetic and genomic information to “personalize” cancer diagnosis and its management. And they are potentially a huge big deal. But, … READ MORE …

SBRT has excellent outcomes for intermediate-risk patients

Stereotactic body radiation therapy or SBRT (sometimes referred to as SABR or SHARP or CyberKnife) has had excellent 7-year outcomes in an update of the consortium study, including data from 10 single-institution trials and two multi-institutional trials. … READ MORE …

A national study of prostate cancer in African Americans

The National Cancer Institute has invested over $20 million in a new study that will attempt to enroll 10,000 African-American men who have been diagnosed with prostate cancer: the RESPOND study. … READ MORE …

Germline mutations and risk for advanced prostate cancer

Many people are increasingly interested in whether genetic testing can help them to understand their risk for cancer. The basic answer is that “Yes, it can.” However, what is also clear is that it is only going to be helpful for a small percentage of the population. … READ MORE …

The “war” on cancer: are we “winning” or “losing” or what?

Clifton Leaf is a cancer survivor. He is also the Editor-in-Chief of Fortune magazine. And he has long argued that we may not be making the most astute decisions about how we are trying to find “the best” and “the rightest” ways to diagnose, treat, and manage cancer. … READ MORE …

Is anyone with intermediate-risk prostate cancer a “good” candidate for AS?

There is no longer any doubt that men initially diagnosed with low- and very low-risk forms of prostate cancer are, in most cases, either excellent or good candidates for first-line management on active surveillance (AS). … READ MORE …